SEC Filing Summary: Access Pharmaceuticals, Inc. (10-Q)
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2010. Access Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments in oncology, cancer supportive care, and diabetes. The company's portfolio includes one FDA-approved product, MuGard (for oral mucositis), and several clinical-stage candidates including ProLindac (Phase 2, ovarian cancer) and Thiarabine (Phase 1/2, hematologic malignancies). The company also holds pre-clinical technologies for oral drug delivery (CobOral) and targeted cancer therapy (CobaCyte).
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2010 | Nine Months Ended Sep 30, 2010 |
|---|---|---|
| Total Revenue | $127,000 | $334,000 |
| Net Loss | $(12,719,000) | $(9,840,000) |
| Net Loss (Common Stockholders) | $(13,171,000) | $(11,180,000) |
| Loss Per Share (Basic/Diluted) | $(0.83) | $(0.73) |
| Cash and Cash Equivalents | $1,496,000 | $1,496,000 |
| Working Capital Deficit | $(12,918,000) | $(12,918,000) |
| Accumulated Deficit | $(252,987,000) | $(252,987,000) |
| Short-term Debt | $5,500,000 | $5,500,000 |
Note: The company reported a net cash burn rate of approximately $500,000 per month for the nine months ended September 30, 2010.
Material Changes vs. Prior Period
- Revenue: Total revenue for the nine months ended September 30, 2010, increased to $334,000 from $248,000 in the prior year period, driven by higher licensing revenue ($281,000 vs. $228,000) and royalties ($53,000 vs. $20,000).
- Operating Expenses: Total operating expenses decreased significantly to $6,213,000 for the nine months ended September 30, 2010, compared to $8,239,000 in 2009. This $2.0 million reduction was primarily due to lower general business consulting fees and reduced accruals for potential liquidated damages.
- Research & Development (R&D): R&D spending increased to $2,718,000 (nine months 2010) from $1,830,000 (nine months 2009), reflecting increased salaries, lab costs, and clinical trial activity for MuGard, ProLindac, and Thiarabine.
- Derivative Accounting Impact: The company recorded a significant non-cash derivative loss of $10,455,000 related to Series A Convertible Preferred Stock in the third quarter of 2010. This was triggered by the possibility of repricing the preferred stock if common stock was sold below $3.00 per share. Conversely, a derivative gain of $6,384,000 was recorded on warrants.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management states that capital resources are adequate to fund operations only into the first quarter of 2011. The company explicitly states it does not have enough capital to achieve long-term goals and must seek additional financing within the next twelve months. Failure to secure funding could jeopardize operations and the ability to continue as a going concern.
- Recent Developments:
- Announced a Phase 2 combination trial for ProLindac in ovarian cancer (November 2010).
- Awarded $1.5 million in government grants under the Patient Protection and Affordable Care Act (November 2010).
- Entered into pre-licensing agreements for CobOral technology and signed a supply agreement for MuGard in China.
- Internal Controls: The company disclosed a material weakness in internal controls over financial reporting. This weakness relates to the lack of segregation of duties and insufficient accounting staff, as all financial reporting is performed by the Chief Financial Officer. Disclosure controls and procedures were deemed ineffective.
- Debt and Dividends: The company has $5.5 million in convertible notes due September 13, 2011. Additionally, $3.95 million in preferred stock dividends were accrued as of September 30, 2010.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to raise capital before Q1 2011 given the stated $500k/month burn rate and $1.5M cash balance.
- Debt Maturity: Confirm the status of the $5.5 million convertible note due in September 2011 and the plan for repayment or refinancing.
- Derivative Liability: Understand the impact of the $10.5 million derivative loss on the balance sheet and how future stock price movements could affect this liability.
- Internal Controls: Assess the timeline and plan for remediation of the material weakness in financial reporting controls.
- Grant Utilization: Monitor the receipt and utilization of the $1.5 million government grant announced in November 2010.